Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT06797401
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT06797401 -
2023-510369-92
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland, Sweden
- Registry status
- Recruiting
Technical summary
Registry record NCT06797401. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-28 (actual); primary completion 2027-05-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
- Condition
- Dyslipidemias
- Intervention (Drug)
- RBD5044
- Intervention (Drug)
- Placebo
- Lead sponsor
- Ribocure Pharmaceuticals AB
Record details
- Record id
cardio:ct-nct06797401- Content hash
cb66e318f61062eed07306a9e8dbbe8cd6e3731fea62f842f6fe83455c54b1a1